Rheumatoid Arthritis
Item
patients with rheumatoid arthritis (ra) as defined by the american college of rheumatology (acr)/european league against rheumatism (eular) 2010
boolean
C0003873 (UMLS CUI [1])
Rheumatoid Arthritis Classification criteria
Item
rheumatoid arthritis classification criteria.
boolean
C0003873 (UMLS CUI [1,1])
C0008902 (UMLS CUI [1,2])
C0243161 (UMLS CUI [1,3])
Rheumatoid Arthritis Functional Status Class
Item
acr class i-iii functional status, based on the 1991 revised criteria.
boolean
C0003873 (UMLS CUI [1,1])
C0598463 (UMLS CUI [1,2])
C0456387 (UMLS CUI [1,3])
Age
Item
patients less than 20 years of age.
boolean
C0001779 (UMLS CUI [1])
Interleukin-6 Antagonist | Interleukin-6 Receptor Antagonist
Item
prior treatment with any biologic anti-interleukin-6 (anti-il-6) or interleukin-6 receptor (il-6r) antagonist.
boolean
C3864917 (UMLS CUI [1])
C3819026 (UMLS CUI [2])
Glucocorticoid Parenteral Injection | Glucocorticoid Intra-Articular Injection
Item
any parenteral or intraarticular glucocorticoid injection within 4 weeks prior to randomization.
boolean
C0017710 (UMLS CUI [1,1])
C1555373 (UMLS CUI [1,2])
C0017710 (UMLS CUI [2,1])
C0021488 (UMLS CUI [2,2])
Prednisone U/day | Equivalent U/day | Prednisone Dosage Change
Item
treatment with prednisone higher than 10 mg or equivalent per day, or change in dosage within 4 weeks prior to randomization.
boolean
C0032952 (UMLS CUI [1,1])
C0456683 (UMLS CUI [1,2])
C0205163 (UMLS CUI [2,1])
C0456683 (UMLS CUI [2,2])
C0032952 (UMLS CUI [3,1])
C0178602 (UMLS CUI [3,2])
C0392747 (UMLS CUI [3,3])
DMARDs | Immunosuppressive Agents | TNF-inhibitors | Biological agents Targeting Rheumatoid Arthritis
Item
treatment with disease-modifying antirheumatic drugs (dmards), immunosuppressive agents, tumor necrosis factor (tnf) antagonists or any other ra-directed biologic agents within a certain amount of time prior to randomization.
boolean
C0242708 (UMLS CUI [1])
C0021081 (UMLS CUI [2])
C3653350 (UMLS CUI [3])
C0005515 (UMLS CUI [4,1])
C1521840 (UMLS CUI [4,2])
C0003873 (UMLS CUI [4,3])
Study Subject Participation Status | Investigational New Drugs | Therapies, Investigational
Item
participation in any clinical research study that evaluated an investigational drug or therapy within 5 half-lives or 60 days of the screening visit, whichever is longer.
boolean
C2348568 (UMLS CUI [1])
C0013230 (UMLS CUI [2])
C0949266 (UMLS CUI [3])
Tuberculosis | Tuberculosis Suspected | High risk of Tuberculosis
Item
active or suspected tuberculosis (tb) or at high risk of contracting tb.
boolean
C0041296 (UMLS CUI [1])
C0041296 (UMLS CUI [2,1])
C0750491 (UMLS CUI [2,2])
C0332167 (UMLS CUI [3,1])
C0041296 (UMLS CUI [3,2])
Fever Treatment required for | Chronic infectious disease Treatment required for | Persistent infection Treatment required for | Recurrent infections Treatment required for
Item
fever, or chronic, persistent, or recurring infection(s) requiring active treatment.
boolean
C0015967 (UMLS CUI [1,1])
C0332121 (UMLS CUI [1,2])
C0151317 (UMLS CUI [2,1])
C0332121 (UMLS CUI [2,2])
C1264606 (UMLS CUI [3,1])
C0332121 (UMLS CUI [3,2])
C0239998 (UMLS CUI [4,1])
C0332121 (UMLS CUI [4,2])
Study Subject Participation Status Consideration Additional
Item
the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
boolean
C2348568 (UMLS CUI [1,1])
C0518609 (UMLS CUI [1,2])
C1524062 (UMLS CUI [1,3])